We are live on
!
Find out more
QC
Quantessence Capital Portfolio holdings
AUM
$20.5M
1-Year Est. Return
71.02%
This Fund
S&P 500
This Quarter
Est. Return
+14.43%
1 Year Est. Return
+71.02%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$340M
AUM Growth
-$60.2M
(-15%)
Cap. Flow
-$87.3M
Cap. Flow
% of AUM
-25.71%
Top 10 Holdings %
Top 10 Hldgs %
46.41%
Holding
483
New
151
Increased
11
Reduced
18
Closed
302
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AZEK
The AZEK Co
AZEK
|
+$58.6M |
| 2 |
RDFN
Redfin
RDFN
|
+$35.6M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$8.53M |
| 4 |
Sprouts Farmers Market
SFM
|
+$7.45M |
| 5 |
Insmed
INSM
|
+$5.79M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$30.3M |
| 2 |
State Street Communication Services Select Sector SPDR ETF
XLC
|
+$12.3M |
| 3 |
ExxonMobil
XOM
|
+$11.3M |
| 4 |
BECN
Beacon Roofing Supply, Inc.
BECN
|
+$10.8M |
| 5 |
Pfizer
PFE
|
+$10.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 31.47% |
| 2 | Real Estate | 13.23% |
| 3 | Healthcare | 10.04% |
| 4 | Financials | 9.26% |
| 5 | Consumer Discretionary | 8.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MPT
176
Medical Properties Trust
MPT
$2.87B
| $86.5K | 0.03% |
20,058
+3,920
| +24% | +$19.4K |
|
177
Lexicon Pharmaceuticals
LXRX
$1.02B
| $79.5K | 0.02% |
+84,098
| New | +$54.5K |
|
178
Wheels Up
UP
$213M
| $71.6K | 0.02% |
+3,348
| New | +$82.3K |
|
179
Evolv Technologies
EVLV
$948M
| $67.8K | 0.02% |
+10,871
| New | +$50.3K |
|
180
Blend Labs
BLND
$409M
| $64.1K | 0.02% |
+19,433
| New | +$65.8K |
|
181
EVgo
EVGO
$213M
| $45.6K | 0.01% |
+12,494
| New | +$42.8K |
|
182
Apple
AAPL
$4.72T
| – | – |
-6,225
| Closed | -$1.38M |
|
183
AbbVie
ABBV
$454B
| – | – |
-10,600
| Closed | -$2.22M |
|
184
Abeona Therapeutics
ABEO
$364M
| – | – |
-26,087
| Closed | -$124K |
|
185
Aclaris Therapeutics
ACRS
$765M
| – | – |
-51,664
| Closed | -$79K |
|
186
Adobe
ADBE
$84.3B
| – | – |
-5,300
| Closed | -$2.03M |
|
187
Atlas Energy Solutions
AESI
$1.63B
| – | – |
-12,100
| Closed | -$216K |
|
188
Affirm
AFRM
$23.8B
| – | – |
-22,727
| Closed | -$1.03M |
|
189
AGCO
AGCO
$8.49B
| – | – |
-3,051
| Closed | -$282K |
|
190
Alamos Gold
AGI
$12.3B
| – | – |
-9,900
| Closed | -$265K |
|
191
AdaptHealth
AHCO
$1.42B
| – | – |
-30,600
| Closed | -$332K |
|
192
American International
AIG
$41.4B
| – | – |
-38,200
| Closed | -$3.32M |
|
193
Alkermes
ALKS
$8.83B
| – | – |
-11,300
| Closed | -$373K |
|
194
Antero Midstream
AM
$10.9B
| – | – |
-48,100
| Closed | -$866K |
|
|
OSG
195
Octave Specialty Group
OSG
$249M
| – | – |
-23,500
| Closed | -$206K |
|
196
Amgen
AMGN
$201B
| – | – |
-12,463
| Closed | -$3.88M |
|
197
Amkor Technology
AMKR
$16.2B
| – | – |
-14,400
| Closed | -$260K |
|
198
Amylyx Pharmaceuticals
AMLX
$1.96B
| – | – |
-40,134
| Closed | -$142K |
|
199
Antero Resources
AR
$10.9B
| – | – |
-7,933
| Closed | -$321K |
|
200
Ascendis Pharma A/S
ASND
$16.6B
| – | – |
-6,788
| Closed | -$1.06M |
|
Similar funds
FS
BC
PMAM
LFA
HAM
DP
SPC
IW
Quantessence Capital's Q2 2025 Portfolio in Review
As of Q2 2025, Quantessence Capital held 483 positions worth $340M, down 15% from $400M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Quantessence Capital withdrew a net $87.3M in Q2 2025, closing 302 positions and reducing 18 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $30.3M position sold in full.
By sector, the portfolio is most concentrated in Industrials at 31% of assets, up from 11% a quarter earlier, followed by Real Estate and Healthcare.
Against the trend, Quantessence Capital opened a new position in The AZEK Co worth $63.6M.
- Quantessence Capital's largest Q2 2025 buy was The AZEK Co: 1,170,131 shares worth $63.6M.
- Quantessence Capital added most to Merck in Q2 2025, an estimated $3.19M increase.
- Quantessence Capital's biggest Q2 2025 reduction was State Street Financial Select Sector SPDR ETF, cutting an estimated $1.84M.
- Quantessence Capital fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $30.3M.
- Quantessence Capital's ten largest holdings make up 46% of its $340M portfolio in Q2 2025.
- Quantessence Capital opened 151 new positions and closed 302 in Q2 2025.
- Quantessence Capital's portfolio value fell 15% quarter-over-quarter to $340M.
Based on Quantessence Capital's 13F filing for Q2 2025, filed 14 Aug 2025.